Logo

NRIX

Nurix Therapeutics, Inc.

NRIX

Nurix Therapeutics, Inc. • NASDAQ
$17.68 ▲ 2.79% (+0.48)
Market Cap $1.36 B
52w High $23.00
52w Low $8.18
Dividend Yield 0%
P/E -5.95
Volume 906.82K
Outstanding Shares 76.88M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $7.894M ▼ $94.279M ▲ $-86.421M ▼ -1.095K% ▼ $-1.03 ▼ $-81.421M ▼
Q2-2025 $44.056M ▲ $14.282M ▲ $-43.464M ▲ -98.656% ▲ $-0.52 ▲ $-46.08M ▲
Q1-2025 $18.453M ▲ $11.654M ▲ $-56.351M ▲ -305.376% ▲ $-0.67 ▲ $-60.514M ▲
Q4-2024 $13.284M ▲ $10.717M ▼ $-58.549M ▼ -440.748% ▼ $-0.75 ▼ $-63.408M ▼
Q3-2024 $12.588M $11.718M $-48.956M -388.91% $-0.67 $-52.217M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $428.829M ▼ $522.472M ▼ $150.22M ▲ $372.252M ▼
Q2-2025 $485.781M ▼ $591.555M ▼ $143.952M ▲ $447.603M ▼
Q1-2025 $549.68M ▼ $615.043M ▼ $134.126M ▼ $480.917M ▼
Q4-2024 $609.583M ▲ $669.343M ▲ $142.35M ▲ $526.993M ▲
Q3-2024 $448.052M $513.6M $136.744M $376.856M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-86.421M ▼ $-57.385M ▲ $50.475M ▼ $1.155M ▲ $-5.755M ▼ $-60.096M ▲
Q2-2025 $-43.464M ▲ $-63.161M ▼ $71.499M ▲ $6K ▼ $8.344M ▲ $-65.836M ▼
Q1-2025 $-56.351M ▲ $-61.087M ▼ $25.533M ▲ $1.473M ▼ $-34.081M ▼ $-64.572M ▼
Q4-2024 $-58.549M ▼ $-48.751M ▼ $-140.817M ▼ $200.521M ▲ $10.953M ▲ $-50.856M ▼
Q3-2024 $-48.956M $-42.177M $-21.339M $45.77M $-17.746M $-44.524M

Revenue by Products

Product Q3-2024Q4-2024Q2-2025Q3-2025
Collaboration Revenue
Collaboration Revenue
 $10.00M ▲$30.00M ▲$10.00M ▼$10.00M ▲
License Revenue
License Revenue
 $0 ▲$0 ▲$30.00M ▲$0 ▼

Five-Year Company Overview

Income Statement

Income Statement Nurix looks like a classic, early‑stage biotech: very little revenue today, mostly from partnerships, and a steady pattern of sizeable losses. Spending on research, clinical development, and overhead clearly outweighs income, so the company is firmly in investment mode rather than earnings mode. Losses have been persistent over the past several years, with some signs of gradual improvement but no line of sight to profitability until and unless key drugs reach approval or major partnership payments ramp up.

Balance Sheet

Balance Sheet The balance sheet is anchored by a large pool of cash and investments, which has grown meaningfully in the most recent period and provides a financial cushion for ongoing R&D. Debt is low, so the company is not heavily leveraged, and most of its funding comes from equity and partnership capital rather than borrowing. This gives Nurix flexibility, but the strength of the balance sheet will depend on how fast that cash is used relative to future inflows from deals or capital raises.

Cash Flow

Cash Flow Cash flow is negative, driven by operating losses as the company funds multiple clinical and discovery programs. Capital spending is modest, so most of the cash burn comes from day‑to‑day operations and R&D rather than big one‑time projects. This pattern is typical for a clinical‑stage biotech: the business consumes cash rather than generates it, and long‑term sustainability rests on access to external funding and eventual success of the drug pipeline. The current reported cash balance suggests a decent runway, but not an indefinite one.

Competitive Edge

Competitive Edge Nurix is positioned in a high‑potential but crowded area: targeted protein degradation. Its DEL‑AI platform, which combines massive DNA‑encoded libraries with machine learning and deep E3 ligase expertise, gives it a differentiated discovery engine that is difficult for new entrants to replicate quickly. Major partnerships with Gilead, Sanofi, and Pfizer both validate the technology and add financial and development support, strengthening its competitive moat. At the same time, it faces intense competition from other TPD players and from companies targeting similar diseases with more established modalities, so clinical performance and speed to market will be critical.

Innovation and R&D

Innovation and R&D Innovation is clearly Nurix’s core strength. The DEL‑AI engine enables it to go after “undruggable” targets and design sophisticated molecules, such as BTK degraders and bifunctional degraders, that can fully remove disease‑driving proteins. The pipeline includes several advanced programs in blood cancers and immuno‑oncology, plus early moves into autoimmune diseases and partnered programs in inflammation and other areas. This breadth increases opportunity but also raises execution risk: success depends on positive trial readouts, smooth regulatory interactions, and the ability to manage multiple complex programs at once.

Summary

Nurix is a high‑science, early‑stage biotech with a powerful discovery platform, strong strategic partners, and a growing pipeline, but it is still far from commercial scale and remains deeply loss‑making. The company’s financial story is typical for its stage: a solid cash position, low debt, and ongoing cash burn funding intensive R&D. Its long‑term outcome will hinge on whether its lead programs deliver compelling clinical data, secure approvals, and convert its technological edge into marketable therapies. For now, Nurix represents a blend of substantial scientific promise and significant clinical, regulatory, and funding uncertainty, as is common in this part of the sector.

NEWS

November 25, 2025 · 7:00 AM UTC

Nurix Therapeutics to Participate in the Piper Sandler 37th Annual Healthcare Conference

Read more

November 10, 2025 · 7:00 AM UTC

Nurix Therapeutics Appoints Accomplished Biopharmaceutical Leader Roger Dansey, M.D., to Its Board of Directors

Read more

November 7, 2025 · 9:00 AM UTC

Nurix Therapeutics Presents New Translational Data from First-in-Human Clinical Trial of Oral CBL-B Inhibitor NX-1607 Demonstrating Immune Activation and Tumor Microenvironment Remodeling

Read more

November 3, 2025 · 9:00 AM UTC

Nurix Therapeutics Announces Presentations at the 67th American Society of Hematology (ASH) Annual Meeting

Read more

October 30, 2025 · 7:00 AM UTC

Nurix Therapeutics to Participate in Upcoming Investor Conferences

Read more